Drug Company To Pay $55M To Settle Federal Securities Fraud Claims
NEW YORK — A drug company will pay $55 million to shareholders to settle claims that it failed to disclose adverse clinical trial results for its nonalcoholic steatohepatitis drug, obeticholic acid...To view the full article, register now.
Already a subscriber? Click here to view full article